Asoprisnil
Chemical compound
- None
- (8S,11R,13S,14S,17S)-11-[4-[(E)-hydroxyiminomethyl]phenyl]-17-methoxy-17-(methoxymethyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
- 199396-76-4 N
- 9577221
- 2883
- 7851660 Y
- 72W09924WP
- D02996 Y
- ChEMBL267431 Y
- DTXSID40904033
- Interactive image
- O=C5\C=C4/C(=C3/[C@@H](c1ccc(\C=N\O)cc1)C[C@]2([C@@H](CC[C@@]2(OC)COC)[C@@H]3CC4)C)CC5
InChI
- InChI=1S/C28H35NO4/c1-27-15-24(19-6-4-18(5-7-19)16-29-31)26-22-11-9-21(30)14-20(22)8-10-23(26)25(27)12-13-28(27,33-3)17-32-2/h4-7,14,16,23-25,31H,8-13,15,17H2,1-3H3/b29-16+/t23-,24+,25-,27-,28+/m0/s1 Y
- Key:GJMNAFGEUJBOCE-MEQIQULJSA-N Y
Asoprisnil (INN; developmental code name J-867) is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids.[1] In 2005, phase III clinical trials were discontinued due to endometrial changes in patients.[2]
See also
References
- v
- t
- e
- See also
- Receptor/signaling modulators
- Glucocorticoids and antiglucocorticoids
- Mineralocorticoid receptor modulators
- List of corticosteroids
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e